The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumors
Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, gives an overview of the ARROW study (NCT03037385), which was designed to evaluate the safety, tolerability and preliminary antineoplastic activity of pralsetinib in patients with medullary thyroid cancer, RET-altered non-small cell lung cancer (NSCLC) and other RET-altered solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
